BlackRock’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-5,274,121
| Closed | -$93.7M | – | 5122 |
|
|
2018
Q3 | $93.7M | Buy |
5,274,121
+65,410
| +1% | +$1.12M | ﹤0.01% | 2016 |
|
|
2018
Q2 | $71.9M | Buy |
5,208,711
+3,497,995
| +204% | +$41.5M | ﹤0.01% | 2144 |
|
|
2018
Q1 | $15.6M | Buy |
1,710,716
+571,925
| +50% | +$3.16M | ﹤0.01% | 2898 |
|
|
2017
Q4 | $4.88M | Buy |
1,138,791
+786,933
| +224% | +$3.75M | ﹤0.01% | 3451 |
|
|
2017
Q3 | $497K | Sell |
351,858
-3,742
| -1% | -$5.21K | ﹤0.01% | 4063 |
|
|
2017
Q2 | $534K | Sell |
355,600
-1,654,369
| -82% | -$3.55M | ﹤0.01% | 4006 |
|
|
2017
Q1 | $5.17M | Buy |
2,009,969
+2,001,206
| +22,837% | +$4.63M | ﹤0.01% | 3373 |
|
|
2016
Q4 | $23K | Sell |
8,763
-1,103
| -11% | -$3.17K | ﹤0.01% | 3221 |
|
|
2016
Q3 | $30K | Hold |
9,866
| – | – | ﹤0.01% | 3175 |
|
|
2016
Q2 | $31K | Buy |
9,866
+6,996
| +244% | +$25.6K | ﹤0.01% | 3132 |
|
|
2016
Q1 | $9K | Buy |
2,870
+1,819
| +173% | +$5.94K | ﹤0.01% | 3221 |
|
|
2015
Q4 | $4K | Hold |
1,051
| – | – | ﹤0.01% | 3222 |
|
|
2015
Q3 | $5K | Hold |
1,051
| – | – | ﹤0.01% | 3044 |
|
|
2015
Q2 | $5K | Hold |
1,051
| – | – | ﹤0.01% | 3140 |
|
|
2015
Q1 | $7K | Hold |
1,051
| – | – | ﹤0.01% | 2950 |
|
|
2014
Q4 | $7K | Hold |
1,051
| – | – | ﹤0.01% | 2978 |
|
|
2014
Q3 | $6K | Hold |
1,051
| – | – | ﹤0.01% | 3036 |
|
|
2014
Q2 | $7K | Buy |
1,051
+226
| +27% | +$2.55K | ﹤0.01% | 3031 |
|
|
2014
Q1 | $20K | Hold |
825
| – | – | ﹤0.01% | 2375 |
|
|
2013
Q4 | $9K | Hold |
825
| – | – | ﹤0.01% | 2811 |
|
|
2013
Q3 | $11K | Hold |
825
| – | – | ﹤0.01% | 2610 |
|
|
2013
Q2 | $11K | Buy |
+825
| New | +$11.1K | ﹤0.01% | 2616 |
|
Other funds holding ECYT
BlackRock's ECYT Position: Q4 2018 in Review
BlackRock sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 5,274,121 shares — an estimated $93.7M sold.
BlackRock first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $93.7M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- BlackRock reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- BlackRock sold 5,274,121 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $93.7M.
- BlackRock first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- BlackRock's Endocyte, Inc. Common Stock position peaked at $93.7M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on BlackRock's 13F filing for Q4 2018, filed 8 Feb 2019.